REFERENCES
1. Lindley SR, Subbaiah KCV, Priyanka F, et al. Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies. Science. 2024;386:762-7.
2. Tasfaout H, Halbert CL, McMillen TS, et al. Split intein-mediated protein trans-splicing to express large dystrophins. Nature. 2024;632:192-200.
3. Tasfaout H, McMillen TS, Reyes TR, et al. Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice. J Clin Invest. 2025:135.
4. Favre D, Di Scala M, Aisa I, et al. Preclinical safety and efficacy of intein-based dual-AAV gene therapy for Stargardt disease. Invest Ophthalmol Vis Sci 2024;65:6089. Available from https://iovs.arvojournals.org/article.aspx?articleid=2800129 [Last accessed on 09 February 2026].
5. Ferla R, Pugni E, Lupo M, et al. Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models. Sci Adv. 2025;11:eadt9354.
6. Philippidis A. 10-Month-old boy makes history as world’s first patient treated with personalized CRISPR therapy. Hum Gene Ther. 2025;36:1016-20.
7. ClinicalTrials.gov. A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) (ASTRA) 2025:ClinicalTrials.gov identifier: NCT0694257. Available from https://clinicaltrials.gov/study/NCT06942572 [Last accessed on 09 February 2026].
8. Mattei AE, Gutierrez AH, Seshadri S, et al. In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies. MAbs. 2024;16:2333729.
9. Walsh RE, Nix A, Ackaert C, et al. Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays. Front Immunol. 2024;15:1406040.
10. Yang TY, Braun M, Lembke W, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther Methods Clin Dev. 2022;26:471-94.
11. Yuan Y, Stumpf FM, Schlor LA, et al. Chemoproteomic discovery of a human RNA ligase. Nat Commun. 2023;14:842.
12. Chen Y, Davidson NM, Wan YK, et al.; SG-NEx consortium. A systematic benchmark of Nanopore long-read RNA sequencing for transcript-level analysis in human cell lines. Nat Methods. 2025;22:801-12.
13. Birhanu AG. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clin Proteomics. 2023;20:32.
14. Wang C, Liu H. Factors influencing degradation kinetics of mRNAs and half-lives of microRNAs, circRNAs, lncRNAs in blood in vitro using quantitative PCR. Sci Rep. 2022;12:7259.
15. Wissel D, Mehlferber MM, Nguyen KM, et al. A systematic benchmark of high-accuracy pacbio long-read RNA sequencing for transcript-level quantification. bioRxiv. 2025.
16. Ule J, Hwang HW, Darnell RB. The future of cross-linking and immunoprecipitation (CLIP). Cold Spring Harb Perspect Biol. 2018;10:a032243.
17. Chen N, Sun K, Chemuturi NV, Cho H, Xia CQ. The perspective of DMPK on recombinant adeno-associated virus-based gene therapy: past learning, current support, and future contribution. AAPS J. 2022;24:31.
18. Moffit JS, Blanset DL, Lynch JL, et al. Regulatory consideration for the nonclinical safety assessment of gene therapies. Hum Gene Ther. 2022;33:1126-41.
19. Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol. 2005;23:1435-9.
20. Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther. 2011;19:36-45.
21. Zhang Y, Duan D. Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum Gene Ther. 2012;23:98-103.
22. Albini S, Palmieri L, Dubois A, Bourg N, Lostal W, Richard I. Assessment of therapeutic potential of a dual AAV approach for duchenne muscular dystrophy. Int J Mol Sci. 2023;24:11421.
23. Davis JR, Banskota S, Levy JM, et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat Biotechnol. 2024;42:253-64.
24. Muller A, Sullivan J, Schwarzer W, et al. High-efficiency base editing in the retina in primates and human tissues. Nat Med. 2025;31:490-501.
25. Riedmayr LM, Hinrichsmeyer KS, Thalhammer SB, et al. mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat Commun. 2023;14:6578.
